Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.99
Peer-review started: January 29, 2015
First decision: March 6, 2015
Revised: April 30, 2015
Accepted: July 16, 2015
Article in press: July 17, 2015
Published online: August 12, 2015
Core tip: Persistent anomalous vitreo-macular adhesion (VMA) is a well-known factor, associated with a variety of sight threatening diseases (macular hole, vitreo-macular traction syndrome, macular edema, exudative age-related macular degeneration). The release of traction has been of exclusive surgical capability. Notwithstanding good results, vitrectomy is hampered by the inability of complete vitreo-retinal separation and surgical complications. With aim to overcome limitations of surgery, investigators have made enormous progress with the advent of pharmacologic vitreolysis - a method for releasing VMA by intravitreal drug delivery. This paper aims to summarize the current knowledge and status of investigation on this new treatment approach.